Pfizer’s Sasanlimab in combination with BCG improves survival in patients with bladder cancer
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
ICMR will continue to track trends in HMPV circulation throughout the year
There was no casualty or loss of human life in the incidence
Subscribe To Our Newsletter & Stay Updated